Mario Maldonado - Concepedia

Author

Mario Maldonado

Novartis (Switzerland)

Also Known As

M. Maldonado, Mario Maldonado

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Ben Taub Hospital Baylor College of Medicine Novartis (United States)Massachusetts General Hospital

About

Mario Maldonado is an author at Novartis (Switzerland) specializing in medicine, diabetes, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	253
2	Diabetes	5	5	184
3	Health Sciences	3	3	84
4	Endocrinology	2	2	49
5	Allergy	1	1	38

Mario Maldonado

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant Peter Trainer, William M Drake, Laurence Katznelson, New England Journal of Medicine	2000	865
A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease Annamaria Colao, Stephan Petersenn, John Newell‐Price, New England Journal of Medicine	2012	636
Ketosis-Prone Diabetes: Dissection of a Heterogeneous Syndrome Using an Immunogenetic and β-Cell Functional Classification, Prospective Analysis, and Clinical Outcomes Mario Maldonado, Christiane S. Hampe, Lakshmi K. Gaur, The Journal of Clinical Endocrinology & Metabolism	2003	224
LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study Xavier Bertagna, Rosario Pivonello, Maria Fleseriu, The Journal of Clinical Endocrinology & Metabolism	2013	183
High variability in baseline urinary free cortisol values in patients with Cushing's disease Stephan Petersenn, John Newell‐Price, James W. Findling, Clinical Endocrinology	2013	143
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase <scp>III</scp> study Rosario Pivonello, Stephan Petersenn, John Newell‐Price, Clinical Endocrinology	2014	116
Presence or absence of a known diabetic ketoacidosis precipitant defines distinct syndromes of “A-β+” ketosis-prone diabetes based on long-term β-cell function, human leukocyte antigen class II alleles, and sex predilection Ramaswami Nalini, Kerem Özer, Mario Maldonado, Metabolism Metabolic SyndromeDiabetes ManagementDiabetes EpidemiologyAutoimmune DiseaseDisease Mechanism	2010	55
Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study Marco Boscaro, Jérôme Bertherat, James W. Findling, Pituitary	2013	50
Psychometric Evaluation of the Cushing’s Quality-of-Life Questionnaire Lauren Nelson, Anna Forsythe, Lori McLeod, Patient Quality Of LifeLife SatisfactionLife AssessmentPsychometric EvaluationMental Health	2013	39
Fenofibrate Is Effective in Treating Hypertriglyceridemia Associated with HIV Lipodystrophy Archana Rao, Susana D’Amico, Ashok Balasubramanyam, The American Journal of the Medical Sciences Metabolic SyndromeFenofibrate Is EffectiveLipid DisorderDiabetesPharmacology	2004	38

Page 1